Complete tracheal duplication with a communicating oesophageal foregut malformation in a dog.

A complete tracheal duplication with a communicating foregut malformation has not been previously reported. We now describe the clinical presentation, computed tomography imaging features and pathological findings associated with this condition in a 12-week-old dog. The dog presented with recurrent episodes of bronchopneumonia and a soft tissue swelling in the ventral cervical region. The main findings were a congenital tracheoesophageal fistula connecting the tracheal and oesophageal anomalies, with secondary moderately neutrophilic bronchopneumonia. In addition, there was a suspected concurrent congenital hypertrophic cardiomyopathy and atrioventricular endocardiosis. This report highlights a novel foregut duplication and may assist in understanding the currently debated aetiopathogenesis of this condition in both humans and animals.

Mycophenolate mofetil and telmisartan for the treatment of proteinuria secondary to minimal change disease podocytopathy in a dog.

A 3-year-old entire female Springer Spaniel, with a previous diagnosis of meningoencephalitis of unknown origin diagnosed 2 years before presentation and treated with long term administration of prednisolone, developed proteinuria. Laboratory findings revealed hypoalbuminemia, hypercholesterolemia, and proteinuria. Further investigations excluded underlying causes. Renal biopsies were performed. The glomeruli and the tubulointerstitial compartment did not show any anomalies on light microscopy and immunofluorescence staining did not reveal abnormalities. Transmission electron microscopy revealed moderate podocyte injury consisting of foot process effacement and microvillus transformation of the cytoplasm. The dog was diagnosed with primary minimal change disease of the podocytes and treated with telmisartan and mycophenolate mofetil. Abnormalities of serum albumin, cholesterol, and proteinuria resolved within 4 weeks. Minimal change disease has been reported in dogs, but this is a case report of proteinuria secondary to minimal change disease successfully treated with mycophenolate mofetil and telmisartan.

Establishing levels of retained radioactivity in cats receiving radioactive iodine treatment.

BACKGROUND: Radioactive iodine (RAI) is considered the gold standard treatment for feline hyperthyroidism. Currently exposure limits to radiation are regulated by national legislation, therefore the length of the isolation period in hospital for cats receiving radioactive treatment varies according to the place where the radioactive facility is located. The aim of this study was to establish when retained radioactivity decreases in cats receiving subcutaneous I-131 to a level that would allow discharge of cats from the hospital while being compliant with current United Kingdom legislation. METHODS: Clinical records of cats treated with subcutaneous I-131 were retrospectively reviewed. Radioactive emission rates were measured using an external probe. Retained radioactivity below 11 MBq at the point of discharge was required by the initial risk assessment to ensure that a 0.3 mSv dose constraint was maintained for owners following standard cat-owner contact restrictions. Average retained activity for each treatment regimen at the time of discharge was calculated. The biological half-life for iodine retention was also calculated. RESULTS: Overall, an end activity below 11 MBq was reached at day 11 in 49% of cats, and at day 13 in 91% of cats. These cats were allowed to be discharged according to UK legislation, as long as contact restrictions were applied at home for 2 weeks. CONCLUSION: Based on our study, an isolation period of 13 days before allowing discharge of cats treated with subcutaneous RAI (I-131) is compliant with current UK legislation.